EVAX

Evaxion Biotech A/S [EVAX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EVAX Stock Summary

Top 10 Correlated ETFs

EVAX


Top 10 Correlated Stocks

EVAX


In the News

01:52 28 Mar 2024 EVAX

EVAX Stock Earnings: Evaxion Biotech Meets EPS for Q4 2023

Evaxion Biotech (NASDAQ: EVAX ) just reported results for the fourth quarter of 2023. Evaxion Biotech reported earnings per share of -$1.60.

08:32 28 Mar 2024 EVAX

Why Is Evaxion Biotech (EVAX) Stock Up 30% Today?

Evaxion Biotech (NASDAQ: EVAX ) stock is on the rise Wednesday after the company revealed a stake held by Merck (NYSE: MRK ). A filing with the Securities and Exchange Commission (SEC) notes that Merck now holds an 11.4% stake in Evaxion Biotech.

03:02 28 Mar 2024 EVAX

Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab

Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.

05:34 28 Mar 2024 EVAX

Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Call Transcript

Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and thank you for standing by.

07:00 28 Mar 2024 EVAX

Evaxion presents promising results on EVX-B1, an AI-designed vaccine against Staphylococcus aureus

COPENHAGEN, Denmark, July 31, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the discovery and development of AI-powered immunotherapies, presents promising results of EVX-B1 at the Staphylococcal Diseases Gordon Research Conference in New Hampshire, USA.

04:30 28 Mar 2024 EVAX

Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

07:48 28 Mar 2024 EVAX

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

COPENHAGEN, Denmark, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.

03:32 28 Mar 2024 EVAX

Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today

High volume penny stocks to watch before next week. The post Best Penny Stocks To Buy: 3 High Volume Stocks To Watch Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

12:03 28 Mar 2024 EVAX

Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

06:00 28 Mar 2024 EVAX

Good Penny Stocks to Add to Your Buy List? 3 to Watch

Which penny stocks are on your buy list right now? The post Good Penny Stocks to Add to Your Buy List?

EVAX Financial details

Company Rating
Neutral
Market Cap
8.48M
Income
-24.47M
Revenue
0
Book val./share
-32.45
Cash/share
0.94
Dividend
-
Dividend %
-
Employees
63
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-0.81
Forward P/E
7.32
PEG
0.32
P/S
-
P/B
-0.22
P/C
3.19
P/FCF
1.52
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-9.42
EPS next Y
0.41
EPS next Q
-4.8
EPS this Y
-22.1%
EPS next Y
-104.35%
EPS next 5Y
-101.38%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-2.38%
-
-
-
-
SMA20
-25%
SMA50
-62.5%
SMA100
-70%
Inst Own
0.34%
Inst Trans
1.12%
ROA
33%
ROE
41%
ROC
0.32%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
0
Shs Float
0
-
-
-
-
Target Price
-
52W Range
2.824-18.5
52W High
-83.33%
52W Low
+50%
RSI
39
Rel Volume
-
Avg Volume
699.27K
Volume
291
Perf Week
-0.99%
Perf Month
-27.71%
Perf Quarter
-65.24%
Perf Half Y
-59.35%
-
-
-
-
Beta
-0.003
-
-
Volatility
0.05%, 0.36%
Prev Close
0%
Price
3
Change
-4.15%

EVAX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.88-5.83-9.27-12.58-9.8
Operating cash flow per share
-1.04-3.66-7.68-11.25-10.9
Free cash flow per share
-1.04-3.69-7.92-11.95-11.03
Cash per share
3.874.983.616.55.58
Book value per share
-0.484.884.34-25.87-30.74
Tangible book value per share
-0.484.884.2816.59-30.74
Share holders equity per share
-0.484.884.34-25.87-30.74
Interest debt per share
4.880.660.152.361.59
Market cap
189.87M189.87M160.2M86.16M41.96M
Enterprise value
191.11M180.35M154.39M57.68M31.03M
P/E ratio
-34.3-16.96-10.67-3.51-1.81
Price to sales ratio
00000
POCF ratio
-95.37-27.02-12.88-3.93-1.63
PFCF ratio
-95.03-26.79-12.49-3.7-1.61
P/B Ratio
-203.9520.2822.76-1.71-0.58
PTB ratio
-203.9520.2822.76-1.71-0.58
EV to sales
00000
Enterprise value over EBITDA
-34.43-16.74-9.44-2.42-1.38
EV to operating cash flow
-95.99-25.67-12.41-2.63-1.2
EV to free cash flow
-95.65-25.45-12.03-2.48-1.19
Earnings yield
-0.03-0.06-0.09-0.28-0.55
Free cash flow yield
-0.01-0.04-0.08-0.27-0.62
Debt to equity
-9.3100-0.07-0.03
Debt to assets
1.02000.09-0.04
Net debt to EBITDA
-0.220.880.361.20.49
Current ratio
0.896.361.188.033.71
Interest coverage
-8.06-8.89-74.3-28.23-16.75
Income quality
0.360.630.830.891.11
Dividend Yield
00000
Payout ratio
0-0.01000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
000.0100
Capex to operating cash flow
00.010.030.060.01
Capex to revenue
00000
Capex to depreciation
-0.09-0.75-3.74-3.95-0.51
Stock based compensation to revenue
00000
Graham number
5.6125.2930.1185.5982.33
ROIC
-0.63-1.07-2.120.580.36
Return on tangible assets
-0.65-1.01-1.27-0.610.39
Graham Net
-1.14.45-0.7412.78-0.5
Working capital
-1.04M9.24M907K30.38M10.21M
Tangible asset value
-931K9.36M6.94M32.34M-72.66M
Net current asset value
-1.06M9.24M907K26.98M251K
Invested capital
-9.3100-0.07-0.03
Average receivables
1.45M851.5K1.36M1.85M1.35M
Average payables
99K392.5K1.65M2.75M2.47M
Average inventory
-682.5K-682.5K-3.46M-4.41M-2.2M
Days sales outstanding
00000
Days payables outstanding
02.91K9.14K3.03K1.33K
Days of inventory on hand
0-0.03-23.86K-2.02K-1.59K
Receivables turnover
00000
Payables turnover
00.130.040.120.27
Inventory turnover
0-13.5K-0.02-0.18-0.23
ROE
5.95-1.2-2.130.490.32
Capex per share
0-0.03-0.24-0.7-0.12

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-11-142022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-2.41-2.85-2.42-2.1-2.05
Operating cash flow per share
07.26000
Free cash flow per share
07.45000
Cash per share
7.515.473.982.630.94
Book value per share
-27.59-30.17-30.530.94-32.45
Tangible book value per share
5.68-30.17-30.530.94-32.45
Share holders equity per share
-27.59-30.17-30.530.94-32.45
Interest debt per share
0.221.180.133.980.07
Market cap
55.06M42.75M29.14M35.45M23.04M
Enterprise value
37.2M31.82M18.9M38.83M20.44M
P/E ratio
-2.4-1.56-1.17-1.56-1.01
Price to sales ratio
00000
POCF ratio
02.44000
PFCF ratio
02.38000
P/B Ratio
-0.84-0.59-0.3713.98-0.26
PTB ratio
-0.84-0.59-0.3713.98-0.26
EV to sales
00000
Enterprise value over EBITDA
-6.92-4.93-3.09-6.9-3.59
EV to operating cash flow
01.82000
EV to free cash flow
01.77000
Earnings yield
-0.1-0.16-0.21-0.16-0.25
Free cash flow yield
00.42000
Debt to equity
0-0.0304.140
Debt to assets
0-0.0400.630
Net debt to EBITDA
3.321.691.68-0.60.46
Current ratio
03.7102.810
Interest coverage
-11.37-11.06-19.61-20.42-31.66
Income quality
0-2.55K000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00.03000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
38.6744.0140.786.6538.72
ROIC
0.090.090.08-0.360.06
Return on tangible assets
-0.210.120.1-0.340.08
Graham Net
1.68-0.5-1.41-1.45-4.36
Working capital
17.85M10.21M10.24M7.32M2.61M
Tangible asset value
13.55M-72.66M-78.72M2.54M-89.76M
Net current asset value
3.96M251K-3.67M-2.85M-12.07M
Invested capital
0-0.0304.140
Average receivables
648K394.5K394.5K2.12M2.12M
Average payables
1.22M1.04M1.04M842.5K842.5K
Average inventory
0-1.25M-1.25M-2.12K-2.12K
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
0.090.090.08-2.240.06
Capex per share
00.18000

EVAX Frequently Asked Questions

What is Evaxion Biotech A/S stock symbol ?

Evaxion Biotech A/S is a DK stock and trading under the symbol EVAX

What is Evaxion Biotech A/S stock quote today ?

Evaxion Biotech A/S stock price is $3 today.

Is Evaxion Biotech A/S stock public?

Yes, Evaxion Biotech A/S is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap